Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Contineum Therapeutics (CTNM) Cash from Financing Activities (2023 - 2026)

Contineum Therapeutics' Cash from Financing Activities history spans 4 years, with the latest figure at $129000.0 for Q1 2026.

  • Quarterly Cash from Financing Activities rose 437.5% to $129000.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $112.8 million through Mar 2026, up 3.44% year-over-year, with the annual reading at $112.7 million for FY2025, 3.38% up from the prior year.
  • Cash from Financing Activities came in at $129000.0 for Q1 2026, down from $93.5 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $108.4 million in Q2 2024 to a low of -$617000.0 in Q1 2023.
  • The 4-year median for Cash from Financing Activities is $129000.0 (2026), against an average of $21.4 million.
  • The largest YoY upside for Cash from Financing Activities was 146861.54% in 2025 against a maximum downside of 99.92% in 2025.
  • Contineum Therapeutics' Cash from Financing Activities stood at -$321000.0 in 2023, then skyrocketed by 300.0% to $642000.0 in 2024, then skyrocketed by 14458.41% to $93.5 million in 2025, then plummeted by 99.86% to $129000.0 in 2026.
  • Per Business Quant, the three most recent readings for CTNM's Cash from Financing Activities are $129000.0 (Q1 2026), $93.5 million (Q4 2025), and $19.1 million (Q3 2025).